VIDEO: Early intraretinal fluid reduction predictive of better outcomes in DME treatment
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Jennifer I. Lim, MD, speaks about the impact of early fluid reduction with anti-VEGF therapy in diabetic macular edema.
A treatment-agnostic analysis of YOSEMITE and RHINE study data for faricimab and aflibercept using a machine learning algorithm showed that early reduction of intraretinal fluid is predictive of better visual acuity and anatomic outcomes.
“The reduction in intraretinal fluid at 3 months is a useful biomarker for predicting anatomic and visual acuity outcomes in eyes with diabetic macular edema at 2 years,” Lim said.
Collapse
Lim J, et al. Impact of early intraretinal fluid reduction on one-year outcomes in diabetic macular edema. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Read more about